Sutent

Covered Uses:	All FDA approved indications not otherwise excluded from Part D. Additional coverage for off-label use is provided for metastatic thyroid cancer.
Exclusion Criteria:	Combination use with other kinase inhibitors (for example, sorafenib, etc).
Required Medical Information:	Coverage is provided for Gastrointestinal stromal tumor when the patient had evidence of disease progression or experienced intolerance while receiving imatinib mesylate (Gleevec).
Age Restrictions:
Prescriber Restrictions:
Coverage Duration:	12 months
Other Criteria:

Last Modified on 12/20/2012